Implicações Medicamentosas a Nível Hepático Em Pacientes Submetidos a Tratamento Da Covid-19

The COVID-19 virus has brought to light a new illness that has raised several questions worldwide, one of which is related to the prophylaxis of the disease, i.e., which drugs can be used to treat the infected patient and what long-term side effects the patient may develop. The aim of the article is to analyze possible hepatic changes in patients undergoing COVID-19 prophylaxis in the ICU, identify the correlation with pharmacological choice, and evaluate long-term side effects. The research was conducted by analyzing electronic medical records of 101 patients undergoing COVID-19 prophylaxis in the ICU in 2020 and 2021. The main observed hepatic changes were in GGT and AST, with the most used medication in the COVID-19 cocktail being azithromycin, associated or not with hydroxychloroquine, ivermectin, or both. The research has some limitations, as it was conducted in only one hospital unit, and therefore, the results cannot be generalized to other regions. However, the significant findings highlight the importance of evaluating the long-term side effects of medications used in COVID-19 prophylaxis, especially in relation to the liver, and considering the correlation with pharmacological choice. This can help improve therapy and prevent serious complications in patients with COVID-19